TBPH Key Statistics, Chart & Performance
The current stock price of TBPH is 20.24 USD. In the past month the price increased by 8.99%. In the past year, price increased by 93.31%.
TBPH Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TBPH. When comparing the yearly performance of all stocks, TBPH is one of the better performing stocks in the market, outperforming 94.7% of all stocks.
TBPH Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TBPH. While TBPH seems to be doing ok healthwise, there are quite some concerns on its profitability.
TBPH Financial Highlights
Over the last trailing twelve months TBPH reported a non-GAAP Earnings per Share(EPS) of -1.05. The EPS decreased by -10.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 36.53% | ||
| ROA | 7.06% | ||
| ROE | 12.61% | ||
| Debt/Equity | 0.14 |
TBPH Forecast & Estimates
13 analysts have analysed TBPH and the average price target is 27.25 USD. This implies a price increase of 34.63% is expected in the next year compared to the current price of 20.24.
For the next year, analysts expect an EPS growth of 277.35% and a revenue growth 71.87% for TBPH
TBPH Ownership
TBPH Latest News, Press Relases and Analysis
About TBPH
Company Profile
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 97 full-time employees. The company went IPO on 2014-05-16. The firm operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
Company Info
THERAVANCE BIOPHARMA INC
Ugland House, South Church Street
GEORGE TOWN GRAND CAYMAN KY1-1104 KY
CEO: Rick E Winningham
Employees: 97
Phone: 16508086000
THERAVANCE BIOPHARMA INC / TBPH FAQ
What does TBPH do?
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 97 full-time employees. The company went IPO on 2014-05-16. The firm operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
What is the current price of TBPH stock?
The current stock price of TBPH is 20.24 USD. The price decreased by -2.41% in the last trading session.
Does THERAVANCE BIOPHARMA INC pay dividends?
TBPH does not pay a dividend.
What is the ChartMill technical and fundamental rating of TBPH stock?
TBPH has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for TBPH stock?
13 analysts have analysed TBPH and the average price target is 27.25 USD. This implies a price increase of 34.63% is expected in the next year compared to the current price of 20.24.
Is THERAVANCE BIOPHARMA INC (TBPH) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TBPH.
Can you provide the upcoming earnings date for THERAVANCE BIOPHARMA INC?
THERAVANCE BIOPHARMA INC (TBPH) will report earnings on 2026-02-24, after the market close.